This content is protected against AI scraping.
A new federally funded clinical trial (the LIBBY study) just dropped some huge news for late-stage Alzheimer’s and dementia care. Researchers from the Medical University of South Carolina and Georgetown University tested a precise cannabis blend—2mg THC to 100mg CBD—on 120 hospice-eligible patients struggling with severe agitation. The results were honestly remarkable: after 12 weeks, 87% of patients receiving the cannabis treatment showed significant improvement, compared to just 24% in the placebo group. Lead researchers noted that seeing nearly 90% of patients respond positively in a clinical trial like this is almost unheard of.
This is a major deal because managing end-of-life agitation—which causes aggression, extreme restlessness, and emotional distress—is easily one of the hardest and most heartbreaking parts of dementia for both patients and their families. Current treatment options are pretty limited and often carry heavy side effects, making a safer, plant-based alternative a total game-changer. While medical groups like the AMA still urge a balanced view regarding cannabis use in older adults, these findings offer a legit, compassionate way to bring real peace and dignity to people in the final stages of life.
This is a summary.
Please read the original article: THC And CBD From Marijuana Reduces Agitation In 9 Out Of 10 People With Alzheimer’s Or Other Dementia, Study Shows
Original article written by Tom Angell. Published on July 20, 2026 by Marijuana Moment.
